➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Merck
Dow
McKesson

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Gimeracil

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Gimeracil?

Gimeracil is an investigational drug.

There have been 67 clinical trials for Gimeracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Quintiles, Inc.

There are one hundred and twenty-seven US patents protecting this investigational drug and nine hundred and ninety-eight international patents.

Recent Clinical Trials for Gimeracil
TitleSponsorPhase
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic CancerLee's Pharmaceutical LimitedPhase 2
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)Yu jirenPhase 2
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerACT GenomicsPhase 2

See all Gimeracil clinical trials

Clinical Trial Summary for Gimeracil

Top disease conditions for Gimeracil
Top clinical trial sponsors for Gimeracil

See all Gimeracil clinical trials

US Patents for Gimeracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gimeracil   Start Trial Metal-salen complex compound, local anesthetic and antineoplastic drug IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP)   Start Trial
Gimeracil   Start Trial Multimodal silica-based nanoparticles   Start Trial
Gimeracil   Start Trial Device and method for drug evaluation and local treatment Kibur Medical, Inc. (Boston, MA)   Start Trial
Gimeracil   Start Trial Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells STC.UNM (Albuquerque, NM)   Start Trial
Gimeracil   Start Trial Pharmaceutical compositions comprising POH derivatives NeOnc Technologies, inc. (Los Angeles, CA)   Start Trial
Gimeracil   Start Trial Medical device for analyte monitoring and drug delivery Theranos, IP Company, LLC (Palo Alto, CA)   Start Trial
Gimeracil   Start Trial Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment CanBas Co., Ltd. (Numazu, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gimeracil

Drugname Country Document Number Estimated Expiration Related US Patent
Gimeracil China CN103781760 2031-06-13   Start Trial
Gimeracil European Patent Office EP2738158 2031-06-13   Start Trial
Gimeracil Japan JP2013001646 2031-06-13   Start Trial
Gimeracil Japan JP5873656 2031-06-13   Start Trial
Gimeracil Russian Federation RU2013156414 2031-06-13   Start Trial
Gimeracil Russian Federation RU2617450 2031-06-13   Start Trial
Gimeracil World Intellectual Property Organization (WIPO) WO2012172892 2031-06-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Merck
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.